Current antidiabetic drugs, such as those related to incretins, do not induce as much β-cell proliferation, and therefore betagenin may offer advantages for the treatment of patients with either type 1 diabetes or type 2 diabetes (T2DM). The gene discussed is GCG; the disease is type 2 diabetes mellitus.